BR112022010907A2 - Uso de isatuximab para o tratamento de mieloma múltiplo recidivante e/ou refratário - Google Patents

Uso de isatuximab para o tratamento de mieloma múltiplo recidivante e/ou refratário

Info

Publication number
BR112022010907A2
BR112022010907A2 BR112022010907A BR112022010907A BR112022010907A2 BR 112022010907 A2 BR112022010907 A2 BR 112022010907A2 BR 112022010907 A BR112022010907 A BR 112022010907A BR 112022010907 A BR112022010907 A BR 112022010907A BR 112022010907 A2 BR112022010907 A2 BR 112022010907A2
Authority
BR
Brazil
Prior art keywords
multiple myeloma
isatuximab
recurring
treatment
refractory multiple
Prior art date
Application number
BR112022010907A
Other languages
English (en)
Portuguese (pt)
Inventor
Risse Marie-Laure
Asset Gaelle
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of BR112022010907A2 publication Critical patent/BR112022010907A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ceramic Products (AREA)
BR112022010907A 2019-12-06 2020-12-04 Uso de isatuximab para o tratamento de mieloma múltiplo recidivante e/ou refratário BR112022010907A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962944809P 2019-12-06 2019-12-06
EP20315186 2020-04-17
US202063023198P 2020-05-11 2020-05-11
US202063037353P 2020-06-10 2020-06-10
US202063094833P 2020-10-21 2020-10-21
PCT/US2020/063468 WO2021113754A1 (en) 2019-12-06 2020-12-04 Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma

Publications (1)

Publication Number Publication Date
BR112022010907A2 true BR112022010907A2 (pt) 2022-10-18

Family

ID=74046182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010907A BR112022010907A2 (pt) 2019-12-06 2020-12-04 Uso de isatuximab para o tratamento de mieloma múltiplo recidivante e/ou refratário

Country Status (13)

Country Link
US (1) US20210171653A1 (https=)
EP (1) EP4069740A1 (https=)
JP (2) JP7704751B2 (https=)
KR (1) KR20220159948A (https=)
CN (1) CN115698065A (https=)
AU (1) AU2020398655A1 (https=)
BR (1) BR112022010907A2 (https=)
CA (1) CA3164026A1 (https=)
CO (1) CO2022009433A2 (https=)
IL (1) IL293615A (https=)
MX (1) MX2022006883A (https=)
TW (1) TWI887310B (https=)
WO (1) WO2021113754A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP6279065B2 (ja) * 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
SG10201803288RA (en) * 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
JP2021502961A (ja) * 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法

Also Published As

Publication number Publication date
US20210171653A1 (en) 2021-06-10
TWI887310B (zh) 2025-06-21
EP4069740A1 (en) 2022-10-12
JP2023505219A (ja) 2023-02-08
MX2022006883A (es) 2022-11-08
AU2020398655A1 (en) 2022-07-28
CA3164026A1 (en) 2021-06-10
JP2025138745A (ja) 2025-09-25
JP7704751B2 (ja) 2025-07-08
CN115698065A (zh) 2023-02-03
WO2021113754A1 (en) 2021-06-10
KR20220159948A (ko) 2022-12-05
TW202133880A (zh) 2021-09-16
CO2022009433A2 (es) 2022-07-29
IL293615A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
WO2019099639A8 (en) Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
MX2018003594A (es) Anticuerpo anti-garp.
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112017018234A2 (pt) inibidores de pd-1 / pd-l1 para o tratamento de câncer
PH12021551451A1 (en) Combination hbv therapy
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
EP4234013A3 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
BR112018011622A2 (pt) método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2020011817A (es) Metodos para tratar el linfoma.
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
MX2019013862A (es) Terapia de combinacion.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112022010907A2 (pt) Uso de isatuximab para o tratamento de mieloma múltiplo recidivante e/ou refratário